Immuno Oncology Product Applications

6 applications found

RNA Technology for Medical Areas of Focus Research

We are currently focusing on 4 medical areas - infectious diseases, immuno-oncology, rare diseases and autoimmune ...

ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)

Pipeline for Immuno-Oncology

AlNovo is pioneering new therapeutic modalities based on our Novobinder Platform to harness the power of the human immune system to directly attack cancer ...

ByAinovo Biotech Inc. based in Sacramento, CALIFORNIA (USA)

Microbiotica Solutions for Clinical Data and Sample Sets

Microbiotica has programs in IBD, Immuno-oncology and Gut Epithelial Barrier Repair developing medicines and biomarkers based on microbiota. ...

ByMicrobiotica Limited based in Little Chesterford, UNITED KINGDOM

TCR and BCR insights for immuno-oncology industry

Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...

ByiRepertoire, Inc. based in Huntsville, ALABAMA (USA)

IGX Platform Software for Immuno-Oncology

Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...

ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS

NK-cell Therapy - Ushering in the Future of NK-cell Therapy

Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...

ByKiadis Pharma NV based in Amsterdam, NETHERLANDS

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you